Chandigarh Herald

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment

 Breaking News
  • No posts were found

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment

April 20
02:45 2023
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease pipeline constitutes 8+ key companies continuously working towards developing 10+ Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Market.

  

Some of the key takeaways from the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease treatment therapies with a considerable amount of success over the years. 
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease companies working in the treatment market are Takeda, Apic Bio, Dicerna Pharmaceuticals, Peak Bio, Arrowhead Pharmaceuticals, Grifols, CSL Behring, Kamada, and others, are developing therapies for the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease treatment 
  • Emerging Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease therapies such as – Prolastin, Aralast NP, Zemaira, Glassia, APB-101, Belcesiran, PHP 303, ARO-AAT, and others are expected to have a significant impact on the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease market in the coming years.  
  • In July 2021, Arrowhead Pharmaceuticals announced that it was granted Breakthrough Therapy designation (BTD) by the USFDA for ARO-AAT, also known as TAK-999, being co-developed with Takeda Pharmaceutical Company as a treatment for there are genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD) 
  • In October 2020, Takeda Pharmaceutical Company Limited and Arrowhead Pharmaceuticals Inc. announced a collaboration and licensing agreement to develop ARO-AAT
  • In August 2019, Arrowhead Pharmaceuticals initiated a placebo-controlled, multi-dose, Phase II study to determine the safety, tolerability and effect on liver histologic parameters in response to ARO-AAT in patients with Alpha-1Antitrypsin Deficiency (AATD) [SEQUOIA]

 

Get a Free Sample PDF Report to know more about Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-liver-disease-pipeline-insight

 

Emerging Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Drugs Under Different Phases of Clinical Development Include:

  • APB-101: Apic Bio
  • Belcesiran: Dicerna Pharmaceuticals
  • PHP 303: Peak Bio
  • ARO-AAT: Arrowhead Pharmaceuticals

 

Route of Administration

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • nhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Therapeutics Assessment

  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Assessment by Product Type
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease By Stage and Product Type
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Assessment by Route of Administration
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease By Stage and Route of Administration
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Assessment by Molecule Type
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease by Stage and Molecule Type

 

DelveInsight’s Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Report covers around 10+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease product details are provided in the report. Download the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease pipeline report to learn more about the emerging Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease therapies

 

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Analysis:

The Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Treatment.
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease drugs and therapies

 

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Market Drivers

  • Increasing investment in the R&D activities for developing novel therapeutics, rise in awareness among people are some of the important factors that are fueling the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Market.

 

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Market Barriers

  • However, lack of diagnostic methods, treatment dosage being poorly standardized and other factors are creating obstacles in the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Market growth.

 

Scope of Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Companies: Takeda, Apic Bio, Dicerna Pharmaceuticals, Peak Bio, Arrowhead Pharmaceuticals, Grifols, CSL Behring, Kamada, and others
  • Key Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Therapies: Prolastin, Aralast NP, Zemaira, Glassia, APB-101, Belcesiran, PHP 303, ARO-AAT, and others
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Therapeutic Assessment: Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease current marketed and Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease emerging therapies
  • Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Market Dynamics: Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease market drivers and Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease market barriers 

 

Request for Sample PDF Report for Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Assessment and clinical trials

 

Table of Contents

1

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Report Introduction

2

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Executive Summary

3

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Overview

4

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Analytical Perspective In-depth Commercial Assessment

5

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Therapeutics

6

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Late Stage Products (Phase II/III)

7

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Mid Stage Products (Phase II)

8

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Early Stage Products (Phase I)

9

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Preclinical Stage Products

10

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Therapeutics Assessment

11

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Key Companies

14

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Key Products

15

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Unmet Needs

16 

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Market Drivers and Barriers

17

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Future Perspectives and Conclusion

18

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight 

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services